Table 4.

Outcomes.

Outcomes
Response to HFRT		n	%
	Best radiographic response (n = 53)
	Decreased size	39	74 %
	Decreased FDG avidity (stable size)	6	11 %
	Stable disease through follow-up	3	6 %
	Progressive disease	5	9 %
	Symptomatic improvement following RT (n = 43)	42	98 %
	Pain medication requirement decrease (n = 32)	6	19 %
Systemic therapy within 1 month after HFRT (n = 51)
	None	7	14 %
	Continued	26	51 %
	Stopped	1	2 %
	New agent	17	33 %
Treatment associated toxicity
	Grade 2acute toxicity (n = 51)	20	39 %
	Fatigue	4	8 %
	Pain Flare	7	14 %
	Dermatitis	8	16 %
	Mucositis/Esophagitis	4	8 %
	Nausea, vomiting or diarrhea	3	6 %
	Grade 3 acute toxicity (n = 51)	1	2 %
	Mucositis	1	2 %
	Late toxicity (n = 51)	7	14 %
	Skin-related	3	6 %
	Pulmonary	2	4 %
	Neurologic	1	2 %
	Dry Mouth	1	2 %
Disease progression during follow-up (median 26 mo)
	Local progression at HFRT target site (n = 53)	8	15 %
	In-field	7	13 %
	Marginal	1	2 %
	Subsequent distant progression (n = 51)	31	61 %
Status at last follow up (n = 49)
	Alive	23	47 %
	Deceased	26	53 %

HFRT: hypofractionated radiation therapy, IQR: interquartile range, n = number of patients.